Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten de Wit

Showing results (41-50 of 205) with videos related to

Pageof 21
Sort By:
The Patient|January 23, 2017
"They Are Talking About Me, but Not with Me": A Focus Group Study to Explore the Patient Perspective on Interprofessional Team Meetings in Primary CareJerôme Jean Jacques van Dongen, Maarten de Wit, Hester Wilhelmina Henrica Smeets, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 24, 2022
American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 RevisionPaul Studenic, Daniel Aletaha, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|October 24, 2022
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revisionPaul Studenic, Daniel Aletaha, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|May 22, 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome setPhilip Rask Lage-Hansen, Nikoletta Svendsen, Jamie Kirkham, et al.
Rheumatic Diseases Clinics of North America|April 17, 2026
Molecular Biomarkers for Predicting Treatment Response in Psoriatic ArthritisAndre Lucas Ribeiro, Anne Barton, Jochen M Schwenk, et al.
Annals of the Rheumatic Diseases|September 23, 2020
Response to: 'Correspondence on 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon <i>et al</i>Xenofon Baraliakos, Laure Gossec, Iain McInnes, et al.
Annals of the Rheumatic Diseases|September 3, 2020
Response to: 'Comment on: 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Gossec <i>et al</i>' by Wei <i>et al</i>Laure Gossec, Xenofon Baraliakos, Iain McInnes, et al.
The Journal of Rheumatology|April 3, 2003
Patients' perspectiveEnid Quest, Gerd Jenny Aanerud, Sylvia Kaarud, et al.
Arthritis Care & Research|December 21, 2016
Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-Sectional Study of 977 PatientsDéborah Puyraimond-Zemmour, Adrien Etcheto, Bruno Fautrel, et al.
Rheumatology (Oxford, England)|September 15, 2023
Tolerability and comparative effectiveness of TNF, IL-17 and IL-23(p19) inhibitors in psoriatic arthritis: a target trial emulation studyZara R Stisen, Sabrina M Nielsen, Marie Skougaard, et al.
Pageof 21

Showing results (41-50 of 205) with videos related to

Sort By:
Pageof 21
The Patient|January 23, 2017
"They Are Talking About Me, but Not with Me": A Focus Group Study to Explore the Patient Perspective on Interprofessional Team Meetings in Primary CareJerôme Jean Jacques van Dongen, Maarten de Wit, Hester Wilhelmina Henrica Smeets, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 24, 2022
American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 RevisionPaul Studenic, Daniel Aletaha, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|October 24, 2022
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revisionPaul Studenic, Daniel Aletaha, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|May 22, 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome setPhilip Rask Lage-Hansen, Nikoletta Svendsen, Jamie Kirkham, et al.
Rheumatic Diseases Clinics of North America|April 17, 2026
Molecular Biomarkers for Predicting Treatment Response in Psoriatic ArthritisAndre Lucas Ribeiro, Anne Barton, Jochen M Schwenk, et al.
Annals of the Rheumatic Diseases|September 23, 2020
Response to: 'Correspondence on 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon <i>et al</i>Xenofon Baraliakos, Laure Gossec, Iain McInnes, et al.
Annals of the Rheumatic Diseases|September 3, 2020
Response to: 'Comment on: 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Gossec <i>et al</i>' by Wei <i>et al</i>Laure Gossec, Xenofon Baraliakos, Iain McInnes, et al.
The Journal of Rheumatology|April 3, 2003
Patients' perspectiveEnid Quest, Gerd Jenny Aanerud, Sylvia Kaarud, et al.
Arthritis Care & Research|December 21, 2016
Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-Sectional Study of 977 PatientsDéborah Puyraimond-Zemmour, Adrien Etcheto, Bruno Fautrel, et al.
Rheumatology (Oxford, England)|September 15, 2023
Tolerability and comparative effectiveness of TNF, IL-17 and IL-23(p19) inhibitors in psoriatic arthritis: a target trial emulation studyZara R Stisen, Sabrina M Nielsen, Marie Skougaard, et al.
Pageof 21